Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers from Mass General Brigham ...
12 hours ago
0
1









